Eli Lilly

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We add Eli Lily and Company (LLY) to CFRA’s High-Quality Capital Appreciation Portfolio. LLY is one of the largest U.S. drug makers in terms of revenue and is a leading developer of drugs in a wide range of therapeutic areas such as endocrinology, which includes a diabetes drug portfolio that generates more than half of its total revenue. We are increasingly optimistic on LLY’s many ongoing efforts, including late-stage therapies such as donanemab (for Alzheimer’s disease), pirtobrutinib (for certain forms of leukemia and lymphoma), and tirzepatide (for sleep apnea and cardiology). Such innovation could complement LLY’s 10 key current drugs, which represent the majority of LLY’s total sales. LLY replaces CVS Health Corporation, which was downgraded to a Hold recommendation.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $56 to $885, reflecting 57.0x our 2025 EPS, justified by LLY’s robust revenue and earnings growth outlook. We lift our 2024 EPS estimate by $0.10 to $12.50 and our 2025 view by $0.06 to $15.53. Leaving behind a year of robust performance in 2023 with top-line revenue growth of 28% Y/Y, we think LLY will continue to outperform peers. We see superior growth prospects for Eli Lilly in the next two years in an environment where competitors will see slower growth and more limited cushion against key drugs’ loss of exclusivities. We updated our model and now expect 2024 revenue growth of 21% Y/Y and another 14% Y/Y in 2025, while we expect record EPS growth of 98% Y/Y and 24%

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/20/2024 7.73% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/16/2024 25.58% Morgan Stanley $805 → $950 Maintains Overweight 02/14/2024 7.73% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 12.36% Truist Securities $650 → $850 Maintains Buy 02/07/2024 6.41% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 7.07% Barclays $680 → $810 Maintains Overweight 02/07/2024 9.05% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 14.34% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 9.05% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 7.73% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -7.47% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight →

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 21.39% Morgan Stanley $805 → $950 Maintains Overweight 02/14/2024 4.14% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 8.61% Truist Securities $650 → $850 Maintains Buy 02/07/2024 2.86% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 3.5% Barclays $680 → $810 Maintains Overweight 02/07/2024 5.42% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 10.53% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 5.42% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 4.14% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -10.56% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -13.11% Barclays $630 → $680 Maintains Overweight 12/21/2023

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/14/2024 8.29% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 12.94% Truist Securities $650 → $850 Maintains Buy 02/07/2024 6.96% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 7.62% Barclays $680 → $810 Maintains Overweight 02/07/2024 9.62% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 14.93% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 9.62% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 8.29% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -6.99% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -9.65% Barclays $630 → $680 Maintains Overweight 12/21/2023 -18.95% Daiwa Capital → $610 Downgrades Buy → Outperform

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $815 price target.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Following LLY’s solid Q4 earnings release this morning, we lift our target price by $86 to $788, 50.9x our projected 2025 EPS, above LLY’s historical forward P/E average, justified by LLY’s strong revenue and earnings growth potential. We raise our 2024 EPS estimate by $0.23 to $12.40, which points to 96% Y/Y growth. We initiate our 2025 view at $15.47. LLY posted Q4 EPS of $2.49 vs. $2.09, a noteworthy +19% Y/Y, $0.12 above the consensus. Q4 revenues of $9.4B, up 28% Y/Y, came in $152M above our estimate and $383M above consensus, driven by higher-than-expected sales for the obesity treatments Mounjaro ($2.2B) and the newly launched Zepbound ($176M). We expect 2024 to be another year of strong growth and pencil in a 19% Y/Y top-line sales

Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/06/2024 16.42% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -0.01% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -2.86% Barclays $630 → $680 Maintains Overweight 12/21/2023 -12.86% Daiwa Capital → $610 Downgrades Buy → Outperform 11/29/2023 -7.15% Truist Securities → $650 Reiterates Buy → Buy 11/20/2023 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/17/2023 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/15/2023 -10.01% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/09/2023 -23.58% Deutsche Bank → $535 Initiates Coverage On → Hold 11/08/2023 — JP Morgan Reiterates → Overweight 11/03/2023 3.13% Morgan Stanley $673

The following is a summary of the Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript: Financial Performance: Eli Lilly’s revenue grew 20% for the full year and 28% for Q4 in 2023; new products contributed over $2 billion growth. Distributed over $1 billion in dividends in Q4, announced a 15% dividend increase for the sixth consecutive year. Q4 revenue increased by 28% compared to Q4 2022 due to acceleration in revenue growth powered by Mounjaro, Verzenio, Jardiance, and Zepbound. Gross margin as a percentage of revenue grew to 82.3% on account of higher realized prices. Operating income rose by 29%, driven by higher revenue from new launches. Earnings per share for Q4 were $2.49, a 19% increase from Q4 2022. U.S. revenue was up by 39% in Q4 owing to the strong performance of Mounjaro, Verzenio, and Zepbound. Q4 revenue for Europe was up by 11%, 15%

Eli Lilly Sees FY Adj EPS $12.20-Adj EPS $12.70.

Eli Lilly (NYSE:LLY) reported quarterly earnings of $2.49 per share which beat the analyst consensus estimate of $2.19 by 13.7 percent. This is a 19.14 percent increase over earnings of $2.09 per share from the same period last year. The company reported quarterly sales of $9.35 billion which beat the analyst consensus estimate of $8.93 billion by 4.74 percent. This is a 28.09 percent increase over sales of $7.30 billion the same period last year.

Eli Lilly: Still Expect Intermittent Delays Fulfilling Orders of Certain Mounjaro Doses Given Significant Demand.